A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma

Maki, R. G., Livingston, P. O., Lewis, J. J., Janetzki, S., Klimstra, D., Desantis, D., Srivastava, P. K., Brennan, M. F. (August 2007) A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci, 52 (8). pp. 1964-72. ISSN 0163-2116 (Print)0163-2116 (Linking)

URL: https://www.ncbi.nlm.nih.gov/pubmed/17420942
DOI: 10.1007/s10620-006-9205-2


We performed a phase I pilot study to determine if autologous vaccine HSPPC-96 (gp96, Oncophage) could be purified from completely resected pancreas adenocarcinomas, to determine patient tolerance of vaccine and to explore immune responses and clinical outcomes of these patients. Subjects were vaccinated with 5 microg of autologous HSPPC-96 weekly for 4 doses. Serial ELISPOT assays of T cells for antitumor reactivity were performed. Subjects received neither adjuvant chemotherapy nor radiation. Ten patients received a full course of vaccinations. No dose-limiting toxicities were encountered. Immediate freezing in liquid nitrogen of the tumor specimen resulted in improved vaccine yield. Median overall survival is 2.2 years (Kaplan-Meier estimate). Autologous anti-HSPPC-96 ELISPOT reactivity increased significantly in 1 of 5 patients examined and a second had an increase of unclear significance. Three of 10 treated patients are alive without disease at 2.6, 2.7, and 5.0 years follow-up. There was no observed correlation between immune response and prognosis. This study demonstrates the feasibility of preparing HSPPC-96 from pancreatic adenocarcinomas. Examination of this novel approach using multiple dose levels is 1 approach to further investigate the immunogenicity and clinical utility of HSPPC-96 vaccination in this setting.

Item Type: Paper
Uncontrolled Keywords: Adenocarcinoma/mortality/surgery/*therapy Aged Cancer Vaccines/*therapeutic use/toxicity Female Heat-Shock Proteins/*therapeutic use/toxicity Humans Immune Tolerance Immunization Schedule Male Middle Aged Pancreatic Neoplasms/surgery/*therapy Pilot Projects T-Lymphocytes/immunology Treatment Outcome
Subjects: diseases & disorders > cancer > cancer types > pancreatic cancer
CSHL Authors:
Communities: CSHL labs > Maki lab
Depositing User: Matt Covey
Date: August 2007
Date Deposited: 26 Oct 2016 19:23
Last Modified: 26 Oct 2016 19:23
Related URLs:
URI: https://repository.cshl.edu/id/eprint/33675

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving